지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Objectives : The purpose of this study was to examine the changes in metabolic parameters and Positive and Negative Syndrome Scale (PANSS) scores of patients previously treated with atypical antipsychotic drugs other than paliperidone, after 8 weeks of treatment with paliperidone. Methods : Changes in body weight, body mass index, leptin, lipid levels, fasting glucose, and PANSS scores of patients who switched from other atypical antipsychotic drugs to paliperidone were measured after 8 weeks of treatment with paliperidone. We compared these results with those of patients who had not been treated with antipsychotic drugs for at least 2 weeks prior to treatment with paliperidone (antipsychotic drug-free patients). Results : The antipsychotic drug-free group (n = 9) did not show significant changes in metabolic parameters, but showed a significant improvement in total and subscale scores of PANSS. In the group that switched from other atypical antipsychotic drugs to paliperidone (n = 13), body weight, body mass index and fasting glucose level significantly increased, while total and subscale scores of PANSS significantly improved. Conclusions : Paliperidone treatment will benefit patients with schizophrenia who have been antipsychotic drug-free or who have had difficulty with other atypical antipsychotic drugs, with regard to their psychopathological state. However, if patients have been treated with other atypical antipsychotic drugs before switching to paliperidone, they could gain body weight or their fasting glucose level could increase over a short period because of a change in receptor number and sensitivity caused by the previously prescribed antipsychotic drugs, and hence, paliperidone should be prescribed with caution for these patients.
목차
등록된 정보가 없습니다.
참고문헌 (33)
참고문헌 신청
Son HI / 2004 / The effect of atypical antipsychotics on weight / Dongguk Journal of Med 11:135~144
이종범 / 2007 / 2세대 항정신병 약물의 대사증후군 / 생물치료정신의학 13(2):138~146
Marino J / 2008 / Paliperidone extended-release for the treatment of schizophrenia / Pharmacotherapy 28:1283~1298
Kane J / 2007 / Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial / Schizophr Res 90:147~161
Davidson M / 2007 / Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study / Schizophr Res 93:117~130
이종범 / 2007 / 2세대 항정신병 약물의 대사증후군 / 생물치료정신의학 13(2):138~146
Marino J / 2008 / Paliperidone extended-release for the treatment of schizophrenia / Pharmacotherapy 28:1283~1298
Kane J / 2007 / Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial / Schizophr Res 90:147~161
Davidson M / 2007 / Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study / Schizophr Res 93:117~130
이 논문의 저자 정보
최근 본 자료
댓글(0)
0